Can DefenCath Continue to Aid CorMedix's Long-Term Growth Ahead?

Key Takeaways CRMD's DefenCath is an FDA-approved catheter lock solution reducing CRBSIs in chronic hemodialysis patients.DefenCath posted $167.6M in nine-month sales in 2025, supported by market exclusivity through 2033.Melinta's acquisition added seven products and boosted CRMD's revenue outlook to $390-$410M for 2025.CorMedix’s (CRMD) lead therapy, DefenCath (taurolidine + heparin), is currently the company’s majority revenue driver.The FDA approved DefenCath in late 2023 as the first and only antimicrob ...